Premium
EQ‐5D‐5L and SF‐6D health utility index scores in patients with myasthenia gravis
Author(s) -
Barnett C.,
Bril V.,
Bayoumi A. M.
Publication year - 2019
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/ene.13836
Subject(s) - medicine , myasthenia gravis , index (typography) , sf 36 , physical therapy , physical medicine and rehabilitation , health related quality of life , disease , world wide web , computer science
Background and purpose Health utilities are a preference‐based method of valuing health states that are used in healthcare research, such as economic evaluations. There are limited health utility valuation data for patients with myasthenia gravis (MG). The aim of the study was to describe health utilities for patients with MG and different health states, using the EQ‐5D‐5L and SF‐6D utility instruments, and to explore clinical and demographic determinants of utilities in this population. Methods Patients completed the EQ‐5D‐5L and SF‐6D. In addition, patients were assessed with the Myasthenia Gravis Foundation of America classification, Myasthenia Gravis Impairment Index and MG‐QOL15 as disease‐specific measures, and the Neuro‐QoL Fatigue scale. We calculated mean utilities for each Myasthenia Gravis Foundation of America severity class. We built regression models for the EQ‐5D‐5L and SF‐6D to determine the clinical and demographic factors that determine patients’ valuation of their health state. Results Among 254 patients, mean EQ‐5D‐5L health utilities were as follows: Remission, 0.94 ± 0.03; Minimal Manifestations, 0.92 ± 0.04; Class I, 0.89 ± 0.06; Class II, 0.78 ± 0.16; Class III, 0.58 ± 0.24 and Class IV, 0.61 ± 0.22. Mean SF‐6D health utilities were as follows: Remission, 0.83 ± 0.07; Minimal Manifestations, 0.86 ± 0.14; Class I, 0.82 ± 0.14; Class II, 0.67 ± 0.12; Class III, 0.56 ± 0.11 and Class IV, 0.50 ± 0.10. The limb/axial scores were more highly correlated to health utilities than ocular or bulbar scores. Conclusions We present estimates of health utilities for patients with MG that can be used in cost‐utility and decision analyses. Limb/axial symptoms had a higher impact on health utilities than ocular or bulbar symptoms, which might reflect the impact of mobility on health valuation.